Endotracheal tubes are medical devices used for intubation into the trachea to maintain an open airway and to administer certain drugs. There are used for mechanical ventilation, thus there is risk for microbial invasion into the airways. Therefore, to prevent or reduce the incidence of hospital acquired infection or ventilator-associated pneumonia (VAP), endotracheal tubes are coated with a drug-releasing coating that releases antimicrobial agents to inhibit bacterial growth and biofilm formation. Coated endotracheal tube includes variety of endotracheal tubes coated with drugs or materials, which offer antimicrobial properties to endotracheal tube. Coatings include heparin, silver, chlorhexidine, rifampicin, and minocycline agents.
Coated endotracheal tubes are advantageous because coatings have a broad-spectrum antimicrobial activity in vitro, that reduces bacterial adhesion and restricts the biofilm formation on the tube surface. This in turn blocks the occurrence of type of hospital-associated infection called ventilator-associated pneumonia. Ventilator-associated pneumonia (VAP) is a type of infection that mainly occurs in patients with mechanical ventilation and it is caused due to the growth of microorganism on the surface of air management devices, thereby causing illness. According to the infectious diseases society of America/American thoracic society guidelines, 2016, VAP develops 48‐72 hours after endotracheal intubation. Moreover, VAP affects 28% of patients who are on mechanical ventilation. Therefore, VAP is an important source of morbidity and mortality in critically ill patients. The mortality rate attributed to VAP is 27% and as high as 43% when the causative agent is antibiotic resistant.
Hence, it is important to prevent VAP infections by replacing the non-coated endotracheal tubes with coated endotracheal tubes. Endotracheal tubes if coated with antibiotic agents such as drugs and silver, will prevent the growth of microorganisms during ventilation. Therefore, increase in incidence of VAP is projected to upsurge the need of coated endotracheal tubes, thus boosting the market growth.
The global Coated Endotracheal Tube market was valued at 1710 million US$ in 2018 and will reach 2820 million US$ by the end of 2025, growing at a CAGR of 6.4% during 2019-2025.
This report focuses on Coated Endotracheal Tube volume and value at global level, regional level and company level. From a global perspective, this report represents overall Coated Endotracheal Tube market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Coated Endotracheal Tube in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Coated Endotracheal Tube manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
C.R. Bard
Bactiguard Holding AB
Enox Biopharma
Hospiteknik Healthcare
Innovative Surface Technologies
N8 Medical, LLC
Sharklet Technologies
Sonoma Pharmaceuticals
Teleflex Incorporated
Venner Medical International
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Orotracheal Intubation
Nasotracheal Intubation
Segment by Application
Anesthesia
Emergency Medicine
Others
Summary:
Get latest Market Research Reports on Coated Endotracheal Tube. Industry analysis & Market Report on Coated Endotracheal Tube is a syndicated market report, published as Global Coated Endotracheal Tube Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Coated Endotracheal Tube market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.